Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 4/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 8/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 7/20 | 0.47 |
| ▸ | BLK | P51451 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.44 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21392902 | 0.86 | TGM2 (0.71) | TGM2LPAR1LPAR2LPAR3BTK | |
| SCHEMBL21392897 | 0.81 | TGM2 (0.60) | TGM2LPAR1LPAR2LPAR3BTK | |
| SCHEMBL9017578 | 0.78 | TGM2 (1.00) | TGM2LPAR1LPAR2LPAR3EGFR | |
| SCHEMBL14341775 | 0.78 | TGM2 (0.86) | TGM2LPAR1LPAR2LPAR3MTNR1A | |
| SCHEMBL8151744 | 0.78 | MTNR1B (0.74) | TGM2LPAR1LPAR2LPAR3MTNR1A | |
| SCHEMBL24168800 | 0.75 | TGM2 (0.66) | TGM2LPAR1LPAR2LPAR3BTK | |
| SCHEMBL22732031 | 0.74 | TGM2 (0.74) | TGM2LPAR1LPAR2LPAR3BTK | |
| SCHEMBL22732028 | 0.73 | TGM2 (0.62) | TGM2LPAR1LPAR2LPAR3BTK | |
| SCHEMBL24168624 | 0.72 | TGM2 (0.61) | TGM2LPAR1LPAR2LPAR3BTK | |
| SCHEMBL24968522 | 0.72 | BRD4 (0.52) | TGM2BTKEGFRBLKERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | TGM2 2225/4885LPAR1 2398/4885LPAR2 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.